Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
7(64%)
Results Posted
50%(1 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
1
9%
Ph phase_2
3
27%
Ph phase_3
6
55%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
6(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(7)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting4
Recruiting3
Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 36 (60.0%)

Trials by Status

terminated19%
active_not_recruiting436%
unknown19%
recruiting327%
completed218%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_3

Remibrutinib Open Label Roll-over Post-trial Access Protocol

NCT07456891
recruitingphase_2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651
active_not_recruitingphase_3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05156281
completedphase_1

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272
active_not_recruitingphase_3

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

NCT06042478
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07456891Phase 3

Remibrutinib Open Label Roll-over Post-trial Access Protocol

Recruiting
NCT06865651Phase 2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

Recruiting
NCT05156281Phase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Active Not Recruiting
NCT07032272Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Completed
NCT06042478Phase 3

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Active Not Recruiting
NCT06868212Phase 3

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Recruiting
NCT05147220Phase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Active Not Recruiting
NCT05976243Phase 3

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Active Not Recruiting
NCT05170724

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Unknown
NCT05432388Phase 2

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Completed
NCT04035668Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11